VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Commentary|Podcasts|October 24, 2023
Independent Rx Forum - NCPA Conference: Legal Update on PBM Litigation
Jack Mozloom, vice president of Public Affairs at the National Community Pharmacists Association (NCPA), speaks with Matt Seiler, general counsel at NCPA, about the current PBM litigation at the 2023 NCPA Convention.
Advertisement
Jack Mozloom, vice president of Public Affairs at the National Community Pharmacists Association (NCPA), speaks with Matt Seiler, general counsel at NCPA, about the current PBM litigation at the 2023 NCPA Convention.
Key Takeaways:
- Osterhaus Pharmacy has filed a class action lawsuit against CVS Health, Caremark, and Aetna, alleging violations of federal antitrust laws and state contract laws related to Medicare Part D prescription fees.
- The lawsuit focuses on the unfair imposition of pharmacy direct and indirect remuneration (DIR) fees, which have been a source of concern for independent pharmacies and their organizations like the NCPA.
- The legal action aims to recover damages and address various claims, including the unfair imposition of fees, breach of good faith and fair dealing, and unjust enrichment.
Advertisement
Related to this article
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
3
Finerenone in Heart Failure: Evidence and Practice a Year Later
4
FDA Approves Zilucoplan Autoinjector for Myasthenia Gravis
5